The purpose of this research study is to test the safety and efficacy of nivolumab after salvage resection in head and neck cancer in patients that have previously received definitive radiation with or without chemotherapy.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percentage of Patients With Grade 3 and 4 Adverse Events of Nivolumab
Timeframe: AEs were collected during the treatment period and for a minimum of 30 days following the last dose of study treatment, up to 7 months.